Involvement of HLADQA1*05 in Patients with Inflammatory Bowel Disease Treated with Anti-TNF Drugs
<i>Background</i>: Over the past decade, TNF inhibitors such as Infliximab and Adalimumab have become central to Inflammatory Bowel Diseases treatment, greatly enhancing patient outcomes. However, immunogenicity—where anti-drug antibodies diminish effectiveness—remains an issue, often re...
Saved in:
Main Authors: | Anna Pau, Ilaria Galliano, Elisa Barnini, Maddalena Dini, Antonio Pizzol, Alice Ponte, Stefano Gambarino, Pier Luigi Calvo, Massimiliano Bergallo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-01-01
|
Series: | Medicina |
Subjects: | |
Online Access: | https://www.mdpi.com/1648-9144/61/1/102 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Therapeutic drug monitoring and neutralizing anti-drug antibody detection to optimize TNF-alpha inhibitor treatment for uveitis
by: Howard C. Chen, et al.
Published: (2025-01-01) -
Inflammatory Bowel Diseases in Children: Modern Achievements in Diagnostics and Therapy
by: A. I. Khavkin, et al.
Published: (2024-01-01) -
Predictors of infliximab efficacy in patients with severe attack of ulcerative colitis
by: A. O. Golovenko, et al.
Published: (2013-10-01) -
Adalimumab-induced optic neuropathy in a patient with Behçet’s syndrome
by: Sofia Miranda, et al.
Published: (2025-01-01) -
Tuberculosis of the tongue in a patient under treatment with adalimumab
by: Cintia Mussi Milani, et al.
Published: (2024-12-01)